Filing Flows › Starling Oncology (STLN) › Q1 2026
Starling Oncology (STLN) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
Starling Oncology (STLN) reported revenue of $147M for the first quarter 2026 (Q1 2026), +41% from a year earlier and +4% from the quarter before. Operating margin was -4.4%, net loss $2.5M (1.7% of revenue).
Starling Oncology, Q1 2026: revenue $147M (+41% year over year), operating margin -4.4%, net loss $2.5M, operating cash flow −$2.2M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $147M | +4% | +41% |
| Operating profit | −$6.5M | — | — |
| Net earnings | −$2.5M | — | — |
| Operating cash flow | −$2.2M | -169% | — |
What changed
Revenue was $147.4M in Q1 2026, up 41% year over year and up 4% from the previous quarter. Specialty Pharmacy was the largest line at 59% of revenue. Specialty Pharmacy added $38.2M year over year (up 78%), 89% of the total change. Clinical trials & other declined 60%.
Operating costs exceeded revenue by $6.5M, an operating margin of -4.4%. Total costs grew 35% against revenue growth of 41%. The fastest-growing cost line was Other operating costs (+41%). The quarter ended with a net loss of $2.5M, narrower than the previous quarter's $7.5M loss. Non-operating items added $4.0M, -161% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$2.2M. Non-cash charges added back $1.6M of depreciation and amortization and $1.7M of share-based compensation. Working capital and other items used $3.0M. Capital expenditures of $1.0M exceeded it, leaving free cash flow of −$3.3M.
Questions
What was Starling Oncology's revenue in the first quarter 2026?
Starling Oncology (STLN) reported revenue of $147M for the first quarter 2026 (Q1 2026), +41% from a year earlier and +4% from the quarter before.
Was Starling Oncology profitable in the first quarter 2026?
Operating loss was $6.5M (-4.4% of revenue) and net loss $2.5M.
Source: Starling Oncology 10-Q on SEC EDGAR.